Fortress Bio's Zycubo Receives FDA Approval for Rare Menkes Disease Treatment.

Fortress Biotech's (FBIO) Zycubo (CUTX-101) copper replacement therapy has been approved by the US FDA for children with Menkes disease, a rare disorder affecting copper metabolism. The approval led to a 10% increase in the company's stock price in the premarket on Tuesday. Menkes disease is estimated to affect 1 in 50,000 newborns.